RTP Mobile Logo
Select Publications

Ascierto PA et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 2020;21(11):1465-77. Abstract

Atkins MB et al. DREAMseq (doublet, randomized evaluation in advanced melanoma sequencing): A phase III trial—ECOG-ACRIN EA6134. ASCO 2021 Plenary Series;Abstract 356154.

Bai X, Flaherty KT. Targeted and immunotherapies in BRAF mutant melanoma: Where we stand and what to expect. Br J Dermatol 2021;185(2):253-62. Abstract

Cheng L et al. Molecular testing for BRAF mutations to inform melanoma treatment decisions: A move toward precision medicine. Mod Pathol 2017;31(1):24-38. Abstract

Dummer R et al. Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma. ASCO 2021;Abstract 9507.

Dummer R et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med 2020;383(12):1139-48. Abstract

Eggermont AMM et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018;378(19):1789-801. Abstract

Gutzmer R et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020;395(10240):1835-44. Abstract

Heinzerling L et al. Tolerability of BRAF/MEK inhibitor combinations: Adverse event evaluation and management. ESMO Open 2019;4(3):e000491. Abstract

Jameson-Lee M et al. Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma. ASCO 2021;Abstract TPS9596.

Long GV et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 2017;377(19):1813-23. Abstract